Clinical Trials Arena July 17, 2025
The acquisition builds upon a previous partnership focused on providing Phase I and II cGMP services for OINDPs.
Aptar Pharma has announced the acquisition of Mod3 Pharma’s clinical trial materials manufacturing capabilities from SWK Holdings.
Mod3 Pharma was previously known as Enteris Biopharma.
This acquisition is a strategic move aimed at strengthening Aptar Pharma’s support for the early-stage development of drugs by providing formulation, fill, and finish services for Phase I and II clinical trials, and promoting the adoption of its devices in early-stage clinical programmes.
It is said to build upon a previous partnership between the two companies, which focused on providing Phase I and II current good manufacturing practices (cGMP) fill and finish services for orally inhaled nasal...
Today's Sponsors
Today's Sponsor